Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
IndustryNovember 17, 2026

Novo Nordisk Trial Shows Semaglutide Cuts BMI in Young Children

A phase 3 trial published Nov. 16 in the New England Journal of Medicine found once-weekly semaglutide reduced BMI by a mean of 13.5% at week 68 in children ages 6 to under 12 with obesity, versus a 2.7% increase with placebo. The STEP Young trial randomized 167 children 2-to-1 to semaglutide or placebo for 104 weeks, with both groups receiving lifestyle counseling; at week 104 the between-group BMI difference was 17.8 percentage points. Adverse events, mostly gastrointestinal, occurred in 96% of the semaglutide group versus 93% on placebo. The study was funded by Novo Nordisk, which makes the drug; Wegovy is currently approved only for adolescents 12 and older, and GLP-1 use among children ages 8 to 11 with obesity rose from 0.03% in 2019 to 9.3% in 2026.

Why it mattersState Medicaid agencies and health plans covering pediatric beneficiaries may face growing pressure to address GLP-1 coverage and prior authorization policy for younger children if the drug eventually gains approval below age 12.

Pharmacy · CHIP

Read the full article at beckershospitalreview.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.